Home » News » January 2025

January, 2025

Potential Impact of Incoming US Government on Australian Business and R&D Tax Policy

January 20th, 2025

Following the US election in 2024, a new Government will be installed in the US during January 2025. The impact of the new Trump Government on US R&D and tax policy is not immediately clear, and it may impact some industries differently to others. Possible impacts may include: there will be a clear push to favor US based manufacturing via tax and tariff measures; media commentary notes that the incoming US president is expected to reduce support for research on the environment […]

Read More

AusIndustry Publishes New Hypothetical Machine Learning Case Study.

August 26th, 2024

AusIndustry have recently published a case study to provide practical examples for eligibility of activities involving machine learning.    It’s probable that this guidance has been in response to a rising number of claims involving AI and ML type activities.   The examples in the case studies will assist R&D entities identify when they might have eligible R&D activities, and what information is relevant for assessing and showing eligibility.   In an earlier Swanson Reed blog post in recent weeks (titled: Assessment of AI related activities […]

Read More

Assessment of AI related activities under the R&D Tax Incentive and potentially emerging compliance focuses

August 12th, 2024

Artificial Intelligence (AI) has been a hot topic in recent years with more companies seeking to utilise the technology in order to capitalise on gains in capability and efficiency. Increasing numbers of companies are investing in AI developments and anecdotally, this probably means an increasing number of companies submitting claims for AI related developments under the R&D Tax Incentive. However, whilst AI is a relatively new and developing field, companies need to be careful not to assume that projects involving […]

Read More

Significant Refundable R&D Offsets receipts reported to the ASX in recent months

July 8th, 2024

Over recent months, a number of companies have reported to the ASX receipt of substantial Refundable R&D Tax Offsets. Notable receipts include: Recce Pharmaceuticals (ASX: RCE) received $2.6 M related to its anti-infective platform; Latrobe Magnesium (ASX: LMG) received $12.5 M related to Magnesium extraction technology; Group 6 Metals (ASX:G6M) received $14.3 M related to processes for producing higher value tungsten products Orthocell Limited (ASX: SNT) received $3.05 M related to its mobility regeneration technology; Botanix (ASX: BOT) received $3 […]

Read More

Categories

Archives